Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Mauro

Showing results (131-140 of 136) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 136 results.
Haematologica|January 12, 2023
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS studyFrancesca R Mauro, Irene Della Starza, Monica Messina, et al.
Haematologica|August 3, 2019
Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemiaFary Diop, Riccardo Moia, Chiara Favini, et al.
American Journal of Hematology|February 26, 2020
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study groupYair Herishanu, Adir Shaulov, Riva Fineman, et al.
Leukemia|July 11, 2020
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL CampusLydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin, et al.
Leukemia|November 2, 2021
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL studyThomas Chatzikonstantinou, Anargyros Kapetanakis, Lydia Scarfò, et al.
American Journal of Hematology|September 29, 2023
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLLAndrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò, et al.
Pageof 14

Showing results (131-140 of 136) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 136 results.
Haematologica|January 12, 2023
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS studyFrancesca R Mauro, Irene Della Starza, Monica Messina, et al.
Haematologica|August 3, 2019
Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemiaFary Diop, Riccardo Moia, Chiara Favini, et al.
American Journal of Hematology|February 26, 2020
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study groupYair Herishanu, Adir Shaulov, Riva Fineman, et al.
Leukemia|July 11, 2020
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL CampusLydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin, et al.
Leukemia|November 2, 2021
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL studyThomas Chatzikonstantinou, Anargyros Kapetanakis, Lydia Scarfò, et al.
American Journal of Hematology|September 29, 2023
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLLAndrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò, et al.
Pageof 14